Evgen Pharma (EVG) Receives “Buy” Rating from Northland Securities
Separately, Northland Capital Partners reaffirmed a buy rating and issued a GBX 113 ($1.48) price target on shares of Evgen Pharma in a research note on Tuesday, September 11th.
Shares of LON:EVG opened at GBX 17.50 ($0.23) on Tuesday. Evgen Pharma has a twelve month low of GBX 12.15 ($0.16) and a twelve month high of GBX 29.25 ($0.38).
Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex for synthesizing and stabilizing the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer.
Featured Article: What are the risks of holding treasury bonds?
Receive News & Ratings for Evgen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.